Reactive compounds and in vitro false positives in HTS

An important component of the successful highthroughput screening (HTS) strategy in drug discovery is the ability to assess HTS structure-activity data, and to distinguish between promising drug leads and the many useless false positives that can plague screening efforts. The author discusses simple...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 1997-09, Vol.2 (9), p.382-384
Main Author: Rishton, Gilbert M.
Format: Article
Language:English
Subjects:
Biological and medical sciences
General pharmacology
Medical sciences
Pharmacology. Drug treatments
Physicochemical properties. Structure-activity relationships
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c485t-ad0a0d7676c67715d3b9659e7259bb62be04a56e30e0df6e7170a3eb15ee265e3
cites
container_end_page 384
container_issue 9
container_start_page 382
container_title Drug discovery today
container_volume 2
creator Rishton, Gilbert M.
description An important component of the successful highthroughput screening (HTS) strategy in drug discovery is the ability to assess HTS structure-activity data, and to distinguish between promising drug leads and the many useless false positives that can plague screening efforts. The author discusses simple chemistry guidelines for the evaluation of ‘positives’ in biochemical screens, with the aim of selecting stable, non-covalent binders (ligands) and eliminating protein-reactive compounds (reagents) from consideration as drug leads at an early stage.
doi_str_mv 10.1016/S1359-6446(97)01083-0
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16081806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644697010830</els_id><sourcerecordid>16081806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-ad0a0d7676c67715d3b9659e7259bb62be04a56e30e0df6e7170a3eb15ee265e3</originalsourceid><addsrcrecordid>eNqFkEFLw0AQhYMoWKs_QchBRA_R2SQ7m5xEilqhINh6Xja7E1hJs3E3LfjvTdrq1dMMvO_NY14UXTK4Y8DwfskyXiaY53hTiltgUGQJHEUTVogi4UWWHg_7L3IanYXwCcDSkuMkwndSurdbirVbd27TmhCr1sS2jbe29y6uVRMo7lywIxVGYb5ankcnO-HiMKfRx_PTajZPFm8vr7PHRaLzgveJMqDACBSoUQjGTVaVyEsSKS-rCtOKIFccKQMCUyMJJkBlVDFOlCKnbBpd7-923n1tKPRybYOmplEtuU2QDKFgBeAA8j2ovQvBUy07b9fKf0sGcmxJ7lqSYwWyFHLXkoTBd3UIUEGrpvaq1Tb8mVNRFpiN2MMeo-HZrSUvg7bUajLWk-6lcfafoB8ZZHp8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16081806</pqid></control><display><type>article</type><title>Reactive compounds and in vitro false positives in HTS</title><source>ScienceDirect Freedom Collection</source><creator>Rishton, Gilbert M.</creator><creatorcontrib>Rishton, Gilbert M.</creatorcontrib><description>An important component of the successful highthroughput screening (HTS) strategy in drug discovery is the ability to assess HTS structure-activity data, and to distinguish between promising drug leads and the many useless false positives that can plague screening efforts. The author discusses simple chemistry guidelines for the evaluation of ‘positives’ in biochemical screens, with the aim of selecting stable, non-covalent binders (ligands) and eliminating protein-reactive compounds (reagents) from consideration as drug leads at an early stage.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/S1359-6446(97)01083-0</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Biological and medical sciences ; General pharmacology ; Medical sciences ; Pharmacology. Drug treatments ; Physicochemical properties. Structure-activity relationships</subject><ispartof>Drug discovery today, 1997-09, Vol.2 (9), p.382-384</ispartof><rights>1997 Elsevier Science Ltd. All rights reserved</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-ad0a0d7676c67715d3b9659e7259bb62be04a56e30e0df6e7170a3eb15ee265e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2798630$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Rishton, Gilbert M.</creatorcontrib><title>Reactive compounds and in vitro false positives in HTS</title><title>Drug discovery today</title><description>An important component of the successful highthroughput screening (HTS) strategy in drug discovery is the ability to assess HTS structure-activity data, and to distinguish between promising drug leads and the many useless false positives that can plague screening efforts. The author discusses simple chemistry guidelines for the evaluation of ‘positives’ in biochemical screens, with the aim of selecting stable, non-covalent binders (ligands) and eliminating protein-reactive compounds (reagents) from consideration as drug leads at an early stage.</description><subject>Biological and medical sciences</subject><subject>General pharmacology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Physicochemical properties. Structure-activity relationships</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNqFkEFLw0AQhYMoWKs_QchBRA_R2SQ7m5xEilqhINh6Xja7E1hJs3E3LfjvTdrq1dMMvO_NY14UXTK4Y8DwfskyXiaY53hTiltgUGQJHEUTVogi4UWWHg_7L3IanYXwCcDSkuMkwndSurdbirVbd27TmhCr1sS2jbe29y6uVRMo7lywIxVGYb5ankcnO-HiMKfRx_PTajZPFm8vr7PHRaLzgveJMqDACBSoUQjGTVaVyEsSKS-rCtOKIFccKQMCUyMJJkBlVDFOlCKnbBpd7-923n1tKPRybYOmplEtuU2QDKFgBeAA8j2ovQvBUy07b9fKf0sGcmxJ7lqSYwWyFHLXkoTBd3UIUEGrpvaq1Tb8mVNRFpiN2MMeo-HZrSUvg7bUajLWk-6lcfafoB8ZZHp8</recordid><startdate>19970901</startdate><enddate>19970901</enddate><creator>Rishton, Gilbert M.</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>19970901</creationdate><title>Reactive compounds and in vitro false positives in HTS</title><author>Rishton, Gilbert M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-ad0a0d7676c67715d3b9659e7259bb62be04a56e30e0df6e7170a3eb15ee265e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Biological and medical sciences</topic><topic>General pharmacology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Physicochemical properties. Structure-activity relationships</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rishton, Gilbert M.</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rishton, Gilbert M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reactive compounds and in vitro false positives in HTS</atitle><jtitle>Drug discovery today</jtitle><date>1997-09-01</date><risdate>1997</risdate><volume>2</volume><issue>9</issue><spage>382</spage><epage>384</epage><pages>382-384</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>An important component of the successful highthroughput screening (HTS) strategy in drug discovery is the ability to assess HTS structure-activity data, and to distinguish between promising drug leads and the many useless false positives that can plague screening efforts. The author discusses simple chemistry guidelines for the evaluation of ‘positives’ in biochemical screens, with the aim of selecting stable, non-covalent binders (ligands) and eliminating protein-reactive compounds (reagents) from consideration as drug leads at an early stage.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><doi>10.1016/S1359-6446(97)01083-0</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1359-6446
ispartof Drug discovery today, 1997-09, Vol.2 (9), p.382-384
issn 1359-6446
1878-5832
language eng
recordid cdi_proquest_miscellaneous_16081806
source ScienceDirect Freedom Collection
subjects Biological and medical sciences
General pharmacology
Medical sciences
Pharmacology. Drug treatments
Physicochemical properties. Structure-activity relationships
title Reactive compounds and in vitro false positives in HTS
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T21%3A10%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reactive%20compounds%20and%20in%20vitro%20false%20positives%20in%20HTS&rft.jtitle=Drug%20discovery%20today&rft.au=Rishton,%20Gilbert%20M.&rft.date=1997-09-01&rft.volume=2&rft.issue=9&rft.spage=382&rft.epage=384&rft.pages=382-384&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/S1359-6446(97)01083-0&rft_dat=%3Cproquest_cross%3E16081806%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-ad0a0d7676c67715d3b9659e7259bb62be04a56e30e0df6e7170a3eb15ee265e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=16081806&rft_id=info:pmid/&rfr_iscdi=true